ArticleNeuromolecular medicine2009
AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models.
Article in Neuromolecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.Scientific reports · 2020Article
- Viral Vector-Based Melanoma Gene Therapy.Biomedicines · 2020Review
- Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.PloS one · 2019Article
- CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.Nature communications · 2018Article
- New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Biologics : targets & therapy · 2018Review
- Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Oncotarget · 2017Review
- Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.Translational oncology · 2016Article
- Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Mini reviews in medicinal chemistry · 2016Review
- Multimodality imaging methods for assessing retinoblastoma orthotopic xenograft growth and development.PloS one · 2014Article
- Immunology of AAV-Mediated Gene Transfer in the Eye.Frontiers in immunology · 2013Review
- Article
- Republished review: Gene therapy for ocular diseases.Postgraduate medical journal · 2011Article
- Enhancers of adeno-associated virus AAV2 transduction via high throughput siRNA screening.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Gene therapy for ocular diseases.The British journal of ophthalmology · 2011Review
- Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.Cancer · 2011Article
- AAV2-mediated in vivo immune gene therapy of solid tumours.Genetic vaccines and therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
Interferon-beta (IFN-beta) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-beta have been hampered by secondary toxicity and the short half-life of IFN-beta in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-beta to tumors. In this study, we tested the efficacy of AAV-mediated local delivery of IFN-beta for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-beta delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-beta consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-beta resulted in efficient retinal infection and sustained IFN-beta production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-beta had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-beta may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.